BetterLife Pharma Inc. (FWB:NPAU) Financings

BetterLife Pharma Inc.

Financings

RaiseDateIn US dollars
Public offering of common shares and pre-funded warrants
Closed: US$100M raised · C$0.25 a share · Bloom Burton Securities Inc. +1
Dealers: Bloom Burton Securities Inc. (lead), Haywood Securities Inc.
Buyers: Deep Track Capital (led the financing); Coastlands Capital (significant co-investment); Marshall Wace (significant co-investment); RA Capital Management (significant co-investment); Perceptive Advisors (significant co-investment); Adage Capital Management (participation); Affinity Asset Advisors (participation); Kalehua Capital (participation); Sphera Fund Management (participation); Squadron Capital Management (participation); Stonepine Capital Management (participation); Woodline Partners LP (participation)
Use of proceeds: Phase 1A, Phase 1B and Phase 2 clinical trials of BETR-001 in cluster headache and migraine, plus working capital and general corporate purposes
Sep 17, 2026
Convertible debenture
Closed: C$2M raised · C$0.06 · 1 warrant at C$0.1 for 36 months
Insiders: A director and insider of the Company subscribed for $2,000,000 of the Debenture; conversion subject to a 19.9% ownership cap absent shareholder approval
Use of proceeds: Complete remaining IND-enabling activities for BETR-001 and general working capital
Jun 22, 2026US$1.41M
Warrant exercise of common shares on exercise of share purchase warrants
Closed: C$25,000 raised
May 6, 2025US$18,138

Read by 6ix AI from the company's releases